LATE-BREAKING ABSTRACT: Two Phase 3 placebo-controlled trials of Aztreonam Lysine for Inhalation (AZLI) for Non-Cystic Fibrosis Bronchiectasis (NCFB)
A. Barker, A. O'Donnell, P. J Thompson, P. Flume, J. Ruzi, J. de Gracia, W. Boersma, E. Polverino, L. Shao, J. Zhang, S. Leitzinger, L. Haas, M. McKevitt, A. B. Montgomery, A. Quittner, D. Gossage, T. O'Riordan (Portland, Washington DC, Charleston, Scottsdale, Foster City, Seattle, Miami, United States Of America; Nedlands, Australia; Barcelona, Spain; Alkmaar, Netherlands)
Source: Annual Congress 2013 –COPD drugs: new findings
Session: COPD drugs: new findings
Session type: Thematic Poster Session
Number: 4136
Disease area: Airway diseases
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
A. Barker, A. O'Donnell, P. J Thompson, P. Flume, J. Ruzi, J. de Gracia, W. Boersma, E. Polverino, L. Shao, J. Zhang, S. Leitzinger, L. Haas, M. McKevitt, A. B. Montgomery, A. Quittner, D. Gossage, T. O'Riordan (Portland, Washington DC, Charleston, Scottsdale, Foster City, Seattle, Miami, United States Of America; Nedlands, Australia; Barcelona, Spain; Alkmaar, Netherlands). LATE-BREAKING ABSTRACT: Two Phase 3 placebo-controlled trials of Aztreonam Lysine for Inhalation (AZLI) for Non-Cystic Fibrosis Bronchiectasis (NCFB). Eur Respir J 2013; 42: Suppl. 57, 4136
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you:
LATE-BREAKING ABSTRACT: Inhaled mannitol for non-cystic fibrosis bronchiectasis: results of a 12 month, multi-centre, double-blind, controlled study. Source: Annual Congress 2013 –Hot topics on airway diseases: new horizons in treatment Year: 2013
Late Breaking Abstract - Effects of long-term Tobramycin Inhalation Solution (TIS) once daily on exacerbation rate in patients with non-cystic fibrosis bronchiectasis. The BATTLE Randomized Controlled Trial Source: Virtual Congress 2020 – ALERT: Infection in adults and children Year: 2020
LATE-BREAKING ABSTRACT: Safety and efficacy of inhaled mannitol over 12 months in high-risk patients with non-CF bronchiectasis Source: International Congress 2014 – Latest insights in airway diseases Year: 2014
LATE-BREAKING ABSTRACT: Baseline demographic profile of subjects of the phase 3 RESPIRE 1 trial of ciprofloxacin dry powder for inhalation (DPI) in non-cystic fibrosis bronchiectasis (NCFB) Source: International Congress 2015 – Bronchiectasis and NTM infections: clinical and functional characterisation Year: 2015
LATE-BREAKING ABSTRACT: Oral corticosteroid-sparing effect of mepolizumab in severe eosinophilic asthma: the SIRIUS study Source: International Congress 2014 – The future has started: emerging potentials for personalised asthma treatment Year: 2014
LATE-BREAKING ABSTRACT: Phase 2a randomized placebo-controlled trial of the oral prostaglandin D2 receptor (DP2/ CRTh2) antagonist QAW039 in eosinophilic asthma Source: International Congress 2014 – The future has started: emerging potentials for personalised asthma treatment Year: 2014
LATE-BREAKING ABSTRACT: The benefits of [italic]Nigella sativa[/italic] oil supplementation on asthma inflammation: A randomised, double-blind, placebo-controlled, phase II trial Source: International Congress 2016 – Novel strategies on COPD and asthma management Year: 2016
LATE-BREAKING ABSTRACT: Prevention of COPD exacerbation by lysozyme: A double-blind, randomized, placebo-controlled study Source: International Congress 2015 – Emerging strategies for airway disease treatments Year: 2015
LATE-BREAKING ABSTRACT: TITLE: Hypertonic Saline in Acute Bronchiolitis: Randomised Controlled Trial (RCT) and Economic Evaluation (The SABRE Study) Source: International Congress 2014 – Prevention, diagnosis and consequences of respiratory infections in children Year: 2014
Bosentan does not improve outcome in patients with steroid-resistant pulmonary sarcoidosis – Results from a double-blind placebo-controlled phase 2 trial Source: International Congress 2014 – Sarcoidosis Year: 2014
LATE-BREAKING ABSTRACT: Reduction in exacerbations with mepolizumab in severe eosinophilic asthma: MENSA study Source: International Congress 2014 – The future has started: emerging potentials for personalised asthma treatment Year: 2014
Late Breaking Abstract - Effectiveness of Fluticasone furoate/vilanterol (FF/VI) compared to usual care (UC) in patients with asthma: The Salford Lung Study (SLS) Source: International Congress 2017 – Late-breaking studies in asthma and COPD Year: 2017
LATE-BREAKING ABSTRACT: A phase 2a study of benralizumab in adults with COPD Source: International Congress 2014 – Latest insights in airway diseases Year: 2014
Roflumilast for stable COPD: Meta-analysis of randomized controlled trials Source: International Congress 2014 – Clinical presentations Year: 2014
Dupilumab (DPL) Efficacy in Patients With Severe Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) with/without Nonsteroidal Anti-inflammatory Drug-Exacerbated Respiratory Disease (NSAID-ERD): SINUS-24, SINUS-52 Trials Source: International Congress 2019 – ALERT: Abstracts Leading to Evolution in Respiratory Medicine Trials: Asthma Year: 2019
Dupilumab (DPL) Improves Upper and Lower Airway Outcomes in Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) with Nonsteroidal Anti-inflammatory Drug-Exacerbated Respiratory Disease (NSAID-ERD): Pooled Results From SINUS-24, SINUS-52 Phase 3 Trials Source: International Congress 2019 – Understanding, monitoring and targeting severe asthma Year: 2019
Safety and Feasibility of Metered CryoSpray (MCS) for Patients with Chronic Bronchitis in COPD: 9 Month Results. Source: International Congress 2019 – Bronchoscopic treatment of COPD: hot news Year: 2019
A Phase 2, double-blind, placebo-controlled study of N–acetylcysteine in combination with pirfenidone in patients with idiopathic pulmonary fibrosis Source: International Congress 2014 – ILDs 6 Year: 2014
Long-term (5 year) safety of bronchial thermoplasty in patients with moderate to severe asthma: Asthma Intervention Research (AIR) Trial Source: Annual Congress 2010 - Aspects of severe asthma Year: 2010
Reslizumab (RES) in patients (pts) with inadequately controlled asthma and elevated blood eosinophils (EOS): Analysis of two phase 3, placebo-controlled trials Source: International Congress 2016 – Asthma: from basic mechanisms to novel therapeutic perspectives Year: 2016